Skip to content

Psilocybin and microdosing: all studies

Page 2 of 6: studies 11 to 20 of 55, newest first. Back to the psilocybin and microdosing overview

Research

Bioactive compounds from Psilocybe cubensis mycelial cultures with transient anxiolytic effects in mice.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society February 1, 2026 Katarzyna Kała, Dorota Bederska‐łojewska, Jan Lazur et al.

The growing percentage of people suffering from drug-resistant depression increases interest in alternative therapies, particularly the usage of psychedelics such as psilocybin. The main source of psilocybin is the Psilocybe cubensis species. Due to the potential therapeutic benefits of psilocybin and the legal restrictions on its possession and use in the form of fungal fruiting bodies, this...

Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis.

Neuroscience and Biobehavioral Reviews 2026 Netta Pinhas, Nofar Eidlman, Avigail Barnea et al. 2 citations

Microdosing - the practice of consuming extremely low doses of classical psychedelic substances that do not elicit overt psychedelic effects - has gained significant attention as a potential method for enhancing cognitive performance. However, findings from controlled studies remain mixed and inconclusive. This preregistered meta-analysis examined the cognitive effects of classical psychedelic...

Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial

November 16, 2025 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. preprint

Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...

Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials

Neuropharmacology November 2, 2025 Luisa Prochazkova, Josephine Marschall, Michiel van Elk et al. 2 citations

BackgroundTaking very small doses of psychedelics (LSD, truffles) over an extended period became prevalent in Western societies for its alleged cognitive benefit, including enhanced creativity. However, in the absence of robust, double-blind-controlled quantitative studies, such claims remain anecdotal.MethodsHere we present results from 3 double-blind placebo-controlled longitudinal trials...

“It Fueled the Fire to Who I Am Now”: Exploring Motivations for Microdosing Psychedelics

Journal of Drug Issues October 31, 2025 Blake Beaton

The emergence of microdosing introduced a novel approach to consuming classic psychedelic substances, such as LSD (lysergic acid diethylamide) and psilocybin mushrooms, in ways previously unconventional. Whereas traditional illicit substance use often seeks euphoric experiences, microdosing deliberately avoids such effects in favor of perceived self-enhancing benefits. Increasingly common in...

Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials

Neuropharmacology October 17, 2025 Luisa Prochazkova, Josephine Marschall, Dominique P. Lippelt et al. 3 citations

ObjectiveMicrodosing psychedelics has been widely reported to enhance focus and problem-solving, sparking interest in its potential to treat attentional disorders such as ADHD. However, existing studies largely rely on anecdotal evidence and lack adequate placebo control.MethodsThis study contributes to the literature by examining the longitudinal effects of microdosing psilocybin truffles in...

DOI: 10.1016/j.neuropharm.2025.110722 (opens in new tab) Psilocybin Cognition Hallucinogen Cognitive assessment system +3

Analysis of Serotonin in Caenorhabditis Elegans Subjected to Micro-Dosing with Psilocybin| Iris Publishers

Insights in Chemistry and Biochemistry October 15, 2025 Douglas B. Craig

method was developed for the analysis of serotonin in Caenorhabditis elegans. Samples were subjected to solvent-solvent extraction from basic conditions into n-heptanol. The serotonin was then back-extracted into acetic acid, the solution diluted into basic buffer, and labelled with 3-(2-furoyl) quinoline-2-carboxaldehyde in the presence of cyanide. The sample was analyzed by capillary...

DOI: 10.33552/icbc.2025.03.000562 (opens in new tab) Caenorhabditis elegans Iris biosensor Capillary electrophoresis Fluorescence +4

Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing days.

Psychopharmacology October 11, 2025 Michelle St Pierre, Elena Argento, Jordyn Cates et al.

Repeated self-administration of small doses of psychedelics, known as microdosing, has been associated with perceived improvements in psychological functioning. However, few studies have examined effects at the daily level. Drawing on data from a naturalistic, prospective, international survey of adults who microdose (N = 1435), we assessed self-reported within-person changes between...

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.

International Journal of Molecular Sciences September 14, 2025 Jacopo Sapienza, Marco Spangaro, Stefano Comai et al. 2 citations

Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In particular, the gene encoding complement component 4 (C4) showed the strongest association with schizophrenia, and this protein is involved in complement-dependent and microglia-mediated synaptic pruning. As a matter of fact, microglia are overactive...

Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes

Neuropharmacology March 7, 2025 Stefan Modzelewski, Anna Stankiewicz, Napoleon Waszkiewicz et al. 5 citations

This review is limited by the heterogeneity in reporting side effects and the short duration of many studies. Future studies should transparently and systematically present a description of side effects.